Stevanato Group

Stevanato Group and DWK Life Sciences Sign Non-Exclusive Distribution Agreement for EZ-fill® Platform Products

Retrieved on: 
Thursday, October 27, 2022
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Packaging, Manufacturing, Stevanato Group, Diagnosis, Biotechnology, Life Sciences Research Office, RTU, NYSE, Drug packaging, Glass, Medication, Total cost, Sale, Solution, Total cost of ownership, Duran (glass), Engineering, Applied science, Group, TCO, Laboratory, Therapy, Fine chemical, Ownership

We are pleased to welcome DWK Life Sciences as a distributor of our EZ-fill platform, said Andrea Zambon, Corporate Business Development Senior Director of Stevanato Group.

Key Points: 
  • We are pleased to welcome DWK Life Sciences as a distributor of our EZ-fill platform, said Andrea Zambon, Corporate Business Development Senior Director of Stevanato Group.
  • Through DWK Life Sciences' established, widespread and specialized network, Stevanato Group aims to broaden the reach of our EZ-fill products into the pharmaceutical ecosystem, from the laboratory to large-scale manufacturing.
  • Michele Mora, Managing Director & Chief Business Officer for DWK Life Sciences, shared: We are excited to partner with Stevanato Group to promote the EZ-fill portfolio and bring the leading RTU primary packaging platform to customers in the DWK Life Sciences global network.
  • DWK Life Sciences is the leading global manufacturer and provider of precision labware as well as primary packaging solutions for Life Science Research, Applied Sciences and Diagnostics and Pharmaceutical markets.

Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

Retrieved on: 
Thursday, October 20, 2022
Quality of life, CA, Parenteral Drug Association, NYSE, Biotechnology, Patient, Program, Ketamine, Group, PDA, Opioid, Stevanato Group, Drug delivery, Biomedicine, Solution, Engineering, Leadership, Fine chemical, Pharmaceutical industry

SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.

Key Points: 
  • SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.
  • This award recognizes the collaboration between Bexson Biomedical and Stevanato Group to optimize Stevanato Group's innovative wearable device On Body Delivery System (OBDS) with Bexson's formulation technology.
  • "It is an honor for Stevanato Group to receive this award, which recognizes the long collaboration with Bexson," adds Stevanato Group's, Paolo Golfetto.
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

PDA Announces 2022 Drug Delivery Innovation Awards Winners

Retrieved on: 
Tuesday, October 18, 2022
Universe, CA, Parenteral Drug Association, Chicago Innovation Awards, Stevanato Group, Electronics, Conference, Syringe, CEO, PDA, Miguel Hernández University of Elche, Pharmaceutical industry

SILVER SPRING, Md., Oct. 18, 2022 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) today announced the winners of the 2022 PDA Drug Delivery Innovation Awards during the opening plenary session of the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices in Palm Springs, CA. Awardees were recognized for their technical innovations in advancing the field of bio/pharmaceutical manufacturing.

Key Points: 
  • The Stevanato Group and Bexson Biomedical earned the the Partnership Innovation Award for the innovation Pain Management Therapy through On-Body Injector System.
  • SILVER SPRING, Md., Oct. 18, 2022 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) today announced the winners of the 2022 PDA Drug Delivery Innovation Awards during the opening plenary session of the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices in Palm Springs, CA.
  • "I want to congratulate the companies that received the 2022 PDA Drug Delivery Innovation Awards," said Richard Johnson, PDA President & CEO.
  • For more information on the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference, click here.

Stevanato Group to Present at Upcoming Investor Conference

Retrieved on: 
Friday, September 9, 2022
Health, Other Health, Other Science, Pharmaceutical, Science, Biotechnology, Group, Solution, Stevanato Group, NYSE, Bank, Conference, BST, Biotechnology, Engineering, Fine chemical

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that management will present at the Bank of America Global Healthcare Conference in London at 9:05 a.m. (BST) on September 15, 2022.

Key Points: 
  • Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that management will present at the Bank of America Global Healthcare Conference in London at 9:05 a.m. (BST) on September 15, 2022.
  • A webcast will be available on the investor section of the Companys website, www.stevanatogroup.com , under the News & Events tab.
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries.
  • The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages.

Stevanato Group and Gerresheimer AG Announce Collaboration on the Development of an Innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Supply Chain Management, Manufacturing, Health, Pharmaceutical, Delivery Services, Health Technology, Cosmetics, Retail, Packaging, Engineering, Partnership, CMOS, NYSE, TCO, Engineering, Solution, Administration, Behavior, Ownership, Saskatchewan River Sturgeon Management Board, Health, Company, EUR, Forward-looking statement, RTU, Cosmetics, Industry, Stevanato Group, Beauty, Pharma, Biotechnology, Group, Ecosystem, Drug development, Environment, Patient, Fine chemical, Vaccine, Gerresheimer

The new solution will be available to other players in the market to standardize fill-finish operations from early phase drug development to commercialization.

Key Points: 
  • The new solution will be available to other players in the market to standardize fill-finish operations from early phase drug development to commercialization.
  • The new RTU solution platform from Stevanato Group and Gerresheimer AG will share the same secondary packaging, production process and sterilization method, ensuring consistent available capacity and a reliable double sourcing to the pharmaceutical industry.
  • A hallmark of the new RTU platform is a significant reduction in particles, improving the overall quality and performance of the RTU solutions.
  • Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus.

Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry

Retrieved on: 
Wednesday, September 7, 2022
Partnership, CMOS, NYSE, TCO, AG, Administration, Solution, Ownership, Saskatchewan River Sturgeon Management Board, RTU, Cosmetics, Industry, Stevanato Group, Beauty, Pharma, Biotechnology, Ecosystem, Drug development, Patient, Fine chemical

This collaboration is projected to help customers gain efficiencies, improve the quality standard, increase speed to market, reduce total cost of ownership (TCO) and help mitigate supply chain risk.

Key Points: 
  • This collaboration is projected to help customers gain efficiencies, improve the quality standard, increase speed to market, reduce total cost of ownership (TCO) and help mitigate supply chain risk.
  • The new solution will be available to other players in the market to standardize fill-finish operations from early phase drug development to commercialization.
  • The new jointly developed vial platform and trademark will be presented in detail to the market at the CPhI Worldwide Frankfurt in November 2022.
  • Our new innovative solution will convince the market to significantly accelerate the conversion from bulk to RTU Vials."

Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry

Retrieved on: 
Wednesday, September 7, 2022
Partnership, CMOS, NYSE, TCO, AG, Administration, Solution, Ownership, Saskatchewan River Sturgeon Management Board, RTU, Cosmetics, Industry, Stevanato Group, Beauty, Pharma, Biotechnology, Ecosystem, Drug development, Patient, Fine chemical

This collaboration is projected to help customers gain efficiencies, improve the quality standard, increase speed to market, reduce total cost of ownership (TCO) and help mitigate supply chain risk.

Key Points: 
  • This collaboration is projected to help customers gain efficiencies, improve the quality standard, increase speed to market, reduce total cost of ownership (TCO) and help mitigate supply chain risk.
  • The new solution will be available to other players in the market to standardize fill-finish operations from early phase drug development to commercialization.
  • The new jointly developed vial platform and trademark will be presented in detail to the market at the CPhI Worldwide Frankfurt in November 2022.
  • Our new innovative solution will convince the market to significantly accelerate the conversion from bulk to RTU Vials."

DGAP-News: Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry

Retrieved on: 
Wednesday, September 7, 2022
Partnership, NYSE, TCO, Solution, Administration, Ownership, Saskatchewan River Sturgeon Management Board, RTU, Cosmetics, Industry, Stevanato Group, Beauty, Pharma, Biotechnology, Ecosystem, Drug development, Patient, Fine chemical

This collaboration is projected to help customers gain efficiencies, improve the quality standard, increase speed to market, reduce total cost of ownership (TCO) and help mitigate supply chain risk.

Key Points: 
  • This collaboration is projected to help customers gain efficiencies, improve the quality standard, increase speed to market, reduce total cost of ownership (TCO) and help mitigate supply chain risk.
  • The new RTU solution platform from Gerresheimer AG and Stevanato Group will share the same secondary packaging, production process and sterilization method, ensuring consistent available capacity and a reliable double sourcing to the pharmaceutical industry.
  • A hallmark of the new RTU platform is a significant reduction in particles, improving the overall quality and performance of the RTU solutions.
  • Our new innovative solution will convince the market to significantly accelerate the conversion from bulk to RTU Vials.

OtterBox launches Industrial Certified Defender Series Division 2 Cases

Retrieved on: 
Thursday, August 25, 2022
UL, Partnership, Mining, Safety, Trust, IPhone 11, OtterBox, Agriculture, Solution, Dust, Man, NPD, Apple, IPad, No, Gas, Multimedia, 2019 Africa Cup of Nations Group F, Entrepreneurship, Risk, Woman, Aviation, IPhone, Division II, Stevanato Group, Risk management, Management, Explosive

FORT COLLINS, Colo. , Aug. 25, 2022 /PRNewswire/ -- Building upon a decade of its popular Defender Series cases, OtterBox introduces its first industrial use-focused solution - Defender Series Division 2 cases for iPhone 11, 12, 13 and iPad mini (6th generation). Certified by UL Solutions, Defender Series Division 2 cases offer device protection from heavy use in certain hazardous industrial settings, which can help improve worksite safety by mitigating explosive hazards that may be present in these harsh environments.

Key Points: 
  • Certified by UL Solutions and built for industrial use, the latest addition to the flagship case line is prepared to handle hazardous environments
    FORT COLLINS, Colo., Aug. 25, 2022 /PRNewswire/ --Building upon a decade of its popular Defender Series cases, OtterBox introduces its first industrial use-focused solution - Defender Series Division 2 cases for iPhone 11, 12, 13 and iPad mini (6th generation).
  • Certified by UL Solutions, Defender Series Division 2 cases offer device protection from heavy use in certain hazardous industrial settings, which can help improve worksite safety by mitigating explosive hazards that may be present in these harsh environments.
  • "Designed for superior protection, seamless connection and maximum efficiency, and certified by UL Solutions, Defender Series Division 2cases safely help teamsstay connected andsystems operate smoothlyin challenginghazardousenvironments."
  • To learn more about Defender Series Division 2 and how OtterBox can safeguard your team's devices in a hazard-filled working environment, visit OtterBoxBusiness.com .

Pre Filled Syringes Global Markets Report 2022: Conventional Prefilled Syringes/Safety Prefilled Syringes - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 28, 2022
Medical Supplies, Health, Forecasting, West Pharmaceutical Services, Geography, COVID-19, Stevanato Group, Demography, GDP, Company, Nipro, Syringe, Becton, Dickinson and Company headquarters, Growth, Baxter International, Borosilicate glass, Pharmaceutical industry, Retail

The "Pre Filled Syringes Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pre Filled Syringes Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • Pre Filled Syringes Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global pre filled syringes market.
  • The Pre Filled Syringes market global report answers all these questions and many more.
  • It compares the pre filled syringes market with other segments of the pre filled syringes market by size and growth, historic and forecast.